Every 8-K that REGEN BIOPHARMA PFD A (RGBPP) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow RGBPP and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RGBPP filings page.
Regen BioPharma, Inc. entered into a Settlement and Mutual Release Agreement with Trillium Partners, LP, resolving $398,740 of claims. After a court fairness hearing under Section 3(a)(10) of the Securities Act and Section 25142 of the California Corporations Code, the company will issue common or Series A preferred shares in tranches. Trillium will receive 65% of the Net Proceeds from sales of these shares until the remitted amount equals the claim.
The company changed its independent auditor after Simon & Edward LLP acquired the attest business of BCRG Group; BCRG was dismissed and Simon & Edward appointed. BCRG’s prior audit opinions for fiscal years ended September 30, 2025 and 2024 were unqualified but included an explanatory paragraph about substantial doubt regarding Regen BioPharma’s ability to continue as a going concern. The board also authorized 1,000 shares of a new Series N Preferred Stock, each carrying 75,000,000 votes, voting together with common and other preferred as a single class, which can significantly concentrate voting power if fully issued.
Regen BioPharma, Inc. issued 77,849,847 common shares between February 4 and February 27, 2026 to settle outstanding obligations. The shares were issued to satisfy $53,474 of principal on convertible indebtedness, $4,249 of accrued interest and $11,000 in incurred fees.
The issuance was conducted as an unregistered private placement under Section 4(a)(2) of the Securities Act of 1933, with no underwriters, commissions or general solicitation, and shares were sold directly through management. As of March 3, 2026, the company had 212,318,424 common shares issued and outstanding.
Regen BioPharma, Inc. reported several unregistered common stock issuances involving debt conversion and a small cash raise. On January 15, 2026 it issued 5,000,000 shares to satisfy $11,449 of principal and $8,101 of accrued interest on convertible indebtedness. On January 29, 2026 it issued 5,302,732 shares to satisfy $12,000 of principal and $1,000 of accrued interest on convertible indebtedness. On January 30, 2026 it issued 11,111,111 shares for cash consideration of $50,000 under a Tier 2 Regulation A offering. All issuances were made without underwriters, with shares sold directly by management. As of February 2, 2026 the company had 129,468,577 common shares issued and outstanding.
Regen Biopharma, Inc. announced a special stock dividend in the form of its authorized but unissued Series A Preferred Stock. Shareholders of record on February 3, 2026 are scheduled to receive the dividend on or about February 9, 2026.
Each eligible holder will receive one share of Series A Preferred Stock for every one share of Regen Biopharma common stock, Series A Preferred Stock, Series AA Preferred Stock, Series M Preferred Stock, and Series NC Preferred Stock owned as of the record date. The dividend is paid entirely in shares, not cash, and applies across these listed classes of the company’s stock.
Regen BioPharma, Inc. filed an 8‑K disclosing unregistered sales of common stock. The company issued 6,800,000 shares on October 8, 2025 for $68,000 under a Tier 2 Regulation A offering sold directly by management.
On October 27, 2025, it issued 3,500,000 shares for $35,000 via Tier 2 Regulation A, and separately issued 4,500,000 shares to satisfy $30,204 of principal and $13,536 of accrued interest on convertible indebtedness under Section 4(a)(2), with no underwriters, commissions, or general solicitation.
On October 28, 2025, Regen issued 7,100,000 shares for $71,000 via Tier 2 Regulation A, and on November 10, 2025, it issued 1,780,000 shares for $17,800 via Tier 2 Regulation A. All Tier 2 Regulation A sales were conducted directly through management.
Regen BioPharma, Inc. disclosed that it raised cash through several unregistered sales of common stock to unaffiliated investors in mid-September 2025. On September 15, 2025 the company issued 3,320,000 common shares for cash consideration of $33,200, on September 16, 2025 it issued 1,000,000 shares for $10,000, and on September 18, 2025 it issued 1,500,000 shares for $15,000.
The shares were issued in reliance on Regulation A exemptions from registration under the Securities Act of 1933. No underwriters were involved, the sales were conducted directly by management without commissions or other consideration paid, and the company states that proceeds from each sale will be used for working capital.